(DXCM) DexCom - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 25.116m USD | Total Return: -18.2% in 12m

Glucose Monitors, Biosensors, Remote Monitoring, Medical Software
Total Rating 59
Safety 82
Buy Signal 0.49
Medical Devices
Industry Rotation: +4.2
Market Cap: 25.1B
Avg Turnover: 331M
Risk 3d forecast
Volatility44.8%
VaR 5th Pctl6.73%
VaR vs Median-11.8%
Reward TTM
Sharpe Ratio-0.40
Rel. Str. IBD26
Rel. Str. Peer Group53.1
Character TTM
Beta0.631
Beta Downside0.822
Hurst Exponent0.515
Drawdowns 3y
Max DD60.95%
CAGR/Max DD-0.25
CAGR/Mean DD-0.44
EPS (Earnings per Share) EPS (Earnings per Share) of DXCM over the last years for every Quarter: "2021-03": 0.08, "2021-06": 0.19, "2021-09": 0.22, "2021-12": 0.17, "2022-03": 0.08, "2022-06": 0.17, "2022-09": 0.28, "2022-12": 0.34, "2023-03": 0.17, "2023-06": 0.34, "2023-09": 0.5, "2023-12": 0.5, "2024-03": 0.32, "2024-06": 0.43, "2024-09": 0.45, "2024-12": 0.38, "2025-03": 0.32, "2025-06": 0.48, "2025-09": 0.61, "2025-12": 0.68, "2026-03": 0.56,
EPS CAGR: 19.29%
EPS Trend: 85.4%
Last SUE: 1.78
Qual. Beats: 1
Revenue Revenue of DXCM over the last years for every Quarter: 2021-03: 505, 2021-06: 595.1, 2021-09: 650.2, 2021-12: 698.2, 2022-03: 628.8, 2022-06: 696.2, 2022-09: 769.6, 2022-12: 815.2, 2023-03: 741.5, 2023-06: 871.3, 2023-09: 975, 2023-12: 1034.5, 2024-03: 921, 2024-06: 1004.3, 2024-09: 994.2, 2024-12: 1113.5, 2025-03: 1036, 2025-06: 1157.1, 2025-09: 1209.3, 2025-12: 1259.6, 2026-03: 1191.9,
Rev. CAGR: 14.50%
Rev. Trend: 98.6%
Last SUE: 0.85
Qual. Beats: 0

Warnings

Overextended 1w

Tailwinds

Confidence

Description: DXCM DexCom

DexCom, Inc. is a medical technology company specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes and metabolic health conditions. Its product portfolio includes the G6 and G7 integrated systems, the Stelo biosensor for non-insulin users, and remote monitoring applications like Dexcom Share. The company utilizes a direct marketing model targeting healthcare professionals, including endocrinologists and diabetes educators, to drive clinical adoption.

The CGM sector is characterized by high barriers to entry due to stringent regulatory requirements for Class II and Class III medical devices. DexCom operates within a recurring revenue framework, where the sale of disposable sensors provides a consistent income stream alongside the initial hardware purchase. Detailed performance metrics and valuation models are available on ValueRay for further analysis. Headquartered in San Diego, the company serves both domestic and international markets through a specialized distribution network.

Headlines to Watch Out For
  • Stelo launch expands total addressable market to non-insulin using type 2 diabetics
  • International expansion of Dexcom ONE+ drives sustainable long-term revenue growth
  • Medicare coverage expansion for basal insulin users increases domestic patient volume
  • Competitive pricing pressure from Abbott Laboratories impacts overall gross profit margins
  • Regulatory approval timelines for next-generation biosensors influence investor sentiment and valuation
Piotroski VR‑10 (Strict) 9.0
Net Income: 930.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.22 > 0.02 and ΔFCF/TA 13.03 > 1.0
NWC/Revenue: 43.75% < 20% (prev 36.56%; Δ 7.19% < -1%)
CFO/TA 0.27 > 3% & CFO 1.78b > Net Income 930.4m
Net Debt (-1.03b) to EBITDA (1.29b): -0.80 < 3
Current Ratio: 1.95 > 1.5 & < 3
Outstanding Shares: last quarter (393.6m) vs 12m ago -3.41% < -2%
Gross Margin: 61.84% > 18% (prev 0.59%; Δ 6.12k% > 0.5%)
Asset Turnover: 71.99% > 50% (prev 61.44%; Δ 10.55% > 0%)
Interest Coverage Ratio: 61.88 > 6 (EBITDA TTM 1.29b / Interest Expense TTM 16.7m)
Altman Z'' 5.20
A: 0.32 (Total Current Assets 4.33b - Total Current Liabilities 2.22b) / Total Assets 6.63b
B: 0.40 (Retained Earnings 2.63b / Total Assets 6.63b)
C: 0.15 (EBIT TTM 1.03b / Avg Total Assets 6.69b)
D: 0.75 (Book Value of Equity 2.74b / Total Liabilities 3.68b)
Altman-Z'' Score: 5.20 = AAA
Beneish M -3.30
DSRI: 0.81 (Receivables 1.11b/1.17b, Revenue 4.82b/4.15b)
GMI: 0.96 (GM 61.84% / 59.43%)
AQI: 0.88 (AQ_t 0.10 / AQ_t-1 0.11)
SGI: 1.16 (Revenue 4.82b / 4.15b)
TATA: -0.13 (NI 930.4m - CFO 1.78b) / TA 6.63b)
Beneish M-Score: -3.30 (Cap -4..+1) = AA
What is the price of DXCM shares? As of May 21, 2026, the stock is trading at USD 71.44 with a total of 11,241,550 shares traded.
Over the past week, the price has changed by +21.97%, over one month by +10.55%, over three months by -2.24% and over the past year by -18.20%.
Is DXCM a buy, sell or hold? DexCom has received a consensus analysts rating of 4.54. Therefore, it is recommended to buy DXCM.
  • StrongBuy: 17
  • Buy: 6
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the DXCM price?
Analysts Target Price 82.4 15.4%
DexCom (DXCM) - Fundamental Data Overview as of 20 May 2026
P/E Trailing = 27.9356
P/E Forward = 23.6967
P/S = 5.2132
P/B = 7.9096
P/EG = 1.1301
Revenue TTM = 4.82b USD
EBIT TTM = 1.03b USD
EBITDA TTM = 1.29b USD
Long Term Debt = 1.24b USD (from longTermDebt, last quarter)
Short Term Debt = 20.5m USD (from shortTermDebt, last quarter)
Debt = 1.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.03b USD (recalculated: Debt 1.38b - CCE 2.42b)
Enterprise Value = 24.09b USD (25.12b + Debt 1.38b - CCE 2.42b)
Interest Coverage Ratio = 61.88 (Ebit TTM 1.03b / Interest Expense TTM 16.7m)
EV/FCF = 16.85x (Enterprise Value 24.09b / FCF TTM 1.43b)
FCF Yield = 5.93% (FCF TTM 1.43b / Enterprise Value 24.09b)
FCF Margin = 29.67% (FCF TTM 1.43b / Revenue TTM 4.82b)
Net Margin = 19.31% (Net Income TTM 930.4m / Revenue TTM 4.82b)
Gross Margin = 61.84% ((Revenue TTM 4.82b - Cost of Revenue TTM 1.84b) / Revenue TTM)
Gross Margin QoQ = 62.95% (prev 62.93%)
Tobins Q-Ratio = 3.63 (Enterprise Value 24.09b / Total Assets 6.63b)
Interest Expense / Debt = 0.22% (Interest Expense 3.10m / Debt 1.38b)
Taxrate = 25.97% (70.0m / 269.5m)
NOPAT = 765.0m (EBIT 1.03b * (1 - 25.97%))
Current Ratio = 1.95 (Total Current Assets 4.33b / Total Current Liabilities 2.22b)
Debt / Equity = 0.47 (Debt 1.38b / totalStockholderEquity, last quarter 2.96b)
Debt / EBITDA = -0.80 (Net Debt -1.03b / EBITDA 1.29b)
Debt / FCF = -0.72 (Net Debt -1.03b / FCF TTM 1.43b)
Total Stockholder Equity = 2.75b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.90% (Net Income 930.4m / Total Assets 6.63b)
RoE = 33.83% (Net Income TTM 930.4m / Total Stockholder Equity 2.75b)
RoCE = 25.88% (EBIT 1.03b / Capital Employed (Equity 2.75b + L.T.Debt 1.24b))
RoIC = 16.65% (NOPAT 765.0m / Invested Capital 4.59b)
WACC = 7.78% (E(25.12b)/V(26.50b) * Re(8.20%) + D(1.38b)/V(26.50b) * Rd(0.22%) * (1-Tc(0.26)))
Discount Rate = 8.20% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -68.89 | Cagr: -2.42%
[DCF] Terminal Value 82.31% ; FCFF base≈1.09b ; Y1≈1.34b ; Y5≈2.29b
[DCF] Fair Price = 109.5 (EV 41.21b - Net Debt -1.03b = Equity 42.24b / Shares 385.9m; r=7.78% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 85.41 | EPS CAGR: 19.29% | SUE: 1.78 | # QB: 1
Revenue Correlation: 98.61 | Revenue CAGR: 14.50% | SUE: 0.85 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.61 | Chg30d=+0.55% | Revisions=+22% | Analysts=20
EPS next Quarter (2026-09-30): EPS=0.67 | Chg30d=-0.61% | Revisions=+0% | Analysts=20
EPS current Year (2026-12-31): EPS=2.58 | Chg30d=+3.50% | Revisions=+77% | GrowthEPS=+23.6% | GrowthRev=+12.1%
EPS next Year (2027-12-31): EPS=3.05 | Chg30d=+1.65% | Revisions=+54% | GrowthEPS=+18.0% | GrowthRev=+11.7%
[Analyst] Revisions Ratio: +77%